- Home
- CRBP vs STRO Comparison
CRBP vs STRO Comparison
Compare CRBP & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- STRO
- Stock Information
- Founded
- CRBP 2009
- STRO 2003
- Country
- CRBP United States
- STRO United States
- Employees
- CRBP N/A
- STRO N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRBP Health Care
- STRO Health Care
- Exchange
- CRBP Nasdaq
- STRO Nasdaq
- Market Cap
- CRBP 143.7M
- STRO 162.9M
- IPO Year
- CRBP N/A
- STRO 2018
- Fundamental
- Price
- CRBP $11.93
- STRO $2.01
- Analyst Decision
- CRBP Strong Buy
- STRO Strong Buy
- Analyst Count
- CRBP 8
- STRO 7
- Target Price
- CRBP $62.00
- STRO $12.14
- AVG Volume (30 Days)
- CRBP 256.8K
- STRO 984.5K
- Earning Date
- CRBP 03-11-2025
- STRO 11-13-2024
- Dividend Yield
- CRBP N/A
- STRO N/A
- EPS Growth
- CRBP N/A
- STRO N/A
- EPS
- CRBP N/A
- STRO N/A
- Revenue
- CRBP N/A
- STRO $160,955,000.00
- Revenue This Year
- CRBP N/A
- STRO N/A
- Revenue Next Year
- CRBP N/A
- STRO N/A
- P/E Ratio
- CRBP N/A
- STRO N/A
- Revenue Growth
- CRBP N/A
- STRO 230.90
- 52 Week Low
- CRBP $7.30
- STRO $1.67
- 52 Week High
- CRBP $61.90
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- CRBP 39.08
- STRO 46.04
- Support Level
- CRBP $11.02
- STRO $1.72
- Resistance Level
- CRBP $13.28
- STRO $2.08
- Average True Range (ATR)
- CRBP 0.74
- STRO 0.14
- MACD
- CRBP 0.16
- STRO 0.05
- Stochastic Oscillator
- CRBP 40.27
- STRO 68.75
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.